Bronchiectasis
Conditions
Keywords
Bronchiectasis, Theophylline, Therapeutic Uses, HDAC, HAT, Random placebo study
Brief summary
Theophylline was well recommended in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. However, there is no supporting evidence for their efficacy in the treatment of bronchiectasis. Our hypothesis is that theophylline will play a role in bronchiectasis. Our purpose is to examine the efficacy and safety of 24 weeks treatment with theophylline in subjects with non-cystic fibrosis bronchiectasis.
Detailed description
For the reasons of lack of sufficient clinical trial evidences, there are no standard therapy recommendations for bronchiectasis. Currently the treatments for bronchiectasis are mostly based on experience gained from the treatment of COPD and cystic fibrosis(CF). The aims of treatment for bronchiectasis are to improve the health-related quality of life, to slow down the decrease of lung function, to reduce the exacerbation frequence and the mortality. The mechanism of treatment are including: treating the underlying disease; improving drainage of sputum; anti-infection; anti-inflammation; treating airway obstruction. A review written by Peter J. Barnes describes that as a bronchodilator in COPD, theophylline may relax human airways smooth muscle, have an anti-inflammation rols, and have an additional effect on mucociliary clearance. Besides, theophylline can improve the activity of histone deacetylase, which will reverse the resistant of corticosteroids. We hypothesis that theophylline will have the same effect in subjects with NCF-bronchiectasis as in subjects with COPD. Our trial may give an evidence of using theophylline in treatment of bronchiectasis.
Interventions
DRUGTheophylline
Theophylline 0.1 bid
DRUGPlacebo(for Theophylline)
Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients between 18-70 years old with non-CF bronchiectasis ,free from acute exacerbations for at least 3 months.Stable phase of the disease.
Exclusion criteria
* Patients with a cigarette smoking history of more than 10 packs-year. Patients with COPD. Patients with traction bronchiectasis due to advanced fibrosis. Patients with known intolerance for theophylline. Patients with asthma. Patients with other disease disturbing outcomes of the trials. Patients without consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scores of the St.George's Respiratory Questionnaire | At 24 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Scores of The Leicester Cough Questionnaire | At 24 weeks | — |
| 24 Hour Sputum Volume | Every day for 24 weeks | — |
| Activity of histone deacetylase(HDAC) | At 24 weeks | HDACs are extracted from cells in blood. |
| Activity of histone acetyltransferase(HAT) | At 24 weeks | HATs are extracted from cells in blood. |
| Lung function | At 24 weeks | Lung function as measured by FEV1, FVC, FEV1%, FEV1/FVC, FEF25-75 values following American Thoracic Society(ATS) guidelines |
| Induced sputum culture | At 24 weeks | — |
| Induced Sputum Cytology Count | At 24 weeks | — |
| Interleukin-6(IL-6) | At 24 weeks | Test IL-6 both in blood and sputum. |
| The Number of Exacerbations | At 24 weeks | — |
| To evaluate change in patients' Clinical Data | Every day for 24 weeks | Clinical Data contain dyspnea, cough, wheezes, hemoptysis, sputum characteristics, sputum volume. |
| Number of participants with adverse events | Up to 24 weeks | Adverse events may contain symptoms such as nausea, sickness, headache, insomnia, palpitation, arrhythmia and so on. Record the symptoms and times of the patients. |
| Plasma Concentration of Theophylline | At 24 weeks | Venous blood was taken for plasma theophylline at the end of the treatment period. (At the very time of 2 hours after patients taken the pills) |
| IL-8 | At 24 weeks | Test IL-8 both in blood and sputum. |
| IL-10 | At 24 weeks | Test IL-10 both in blood and sputum. |
| Human Tumor Necrosis Factor α（TNF-α) | At 24 weeks | Test TNF-α both in blood and sputum. |
| 8-Isoprostane | At 24 weeks | — |
| Blood routine examination | At 24 weeks | — |
| C-Reactive Protein | At 24 weeks | — |
Countries
China
Outcome results
None listed